Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4705401 | 0.83 | POLB (0.37) | KDM4EGAAPOLBMEN1ALDH1A1 | |
| SCHEMBL4705550 | 0.80 | KDM4E (0.42) | KDM4EGAAPOLBSMN1; SMN2 | |
| SCHEMBL4705570 | 0.77 | MAPT (0.37) | KDM4EGAAPOLBMEN1ALDH1A1 | |
| SCHEMBL13670443 | 0.74 | KDM4E (0.38) | KDM4EGAAPOLBMEN1ALDH1A1 | |
| SCHEMBL4706103 | 0.72 | PNMT (0.35) | — | |
| SCHEMBL4703109 | 0.69 | KDM4E (0.56) | KDM4EPOLBMEN1ALDH1A1KMT2A | |
| SCHEMBL4701697 | 0.69 | KDM4E (0.40) | KDM4EGAAPOLBALDH1A1KMT2A | |
| SCHEMBL5242785 | 0.65 | ALDH1A1 (0.36) | KDM4EGAAMEN1ALDH1A1KMT2A | |
| SCHEMBL14955079 | 0.65 | SMN1; SMN2 (0.63) | KDM4EGAAALDH1A1KMT2ARAB9A | |
| SCHEMBL14954856 | 0.64 | MAPT (0.50) | KDM4EGAAMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1871776-A2 | FUSED THIENO[2,3-B]PYRIDINE AND THIAZOLO[5,4-B]PYRIDINE COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20060247320-A1 | Compounds for inhibiting KSP kinesin activity | SCHERING CORPORATION | 2006-11-02 | — | — | US | disclosed |
| WO-2006098961-A2 | FUSED THIENO [2, 3-B] PYRIDINE AND THIAZOLO [5, 4-B] PYRIDINE COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247320-A1 | Compounds for inhibiting KSP kinesin activity | KIFC1, KIF5B, KIF2C | KDM4E 501/4885GAA 1311/4885POLB 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.